Delivery Order SPE2DB22D2211-SPE2DB25FSELA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ramelteon 8 mg tablets in unit-dose packaging (50-count) valued at $2,315.08. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a competitive award with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $6,147.26 to AmerisourceBergen Drug Corp for Ramelteon 8 mg tablets (50-unit dose packaging) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ramelteon 8 mg tablets (100-count) with a contract value of $2,035.44. This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award involves no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ramelteon 8 mg tablets (100-count units) with a contract ceiling value of $3,606.44. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The ultimate completion date is August 14, 2025, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,039.56 to AmerisourceBergen Drug Corp for 30 tablets of Ramelteon 8 mg, a medication used to treat insomnia. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ramelteon 8 mg tablets in unit dose packaging (50 count) with a firm fixed price ceiling value of $2,669.48. This non-set-aside competitive award is scheduled for completion by August 5, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor...
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,177,965 units of the sleep medication Ramelteon 8 mg Tablet 30s. The $1,415.04 contract has a performance period through May 8, 2025 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global...
- The Defense Logistics Agency awarded a $246,000 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 30,000 units of 8mg Ramelteon tablets. As a major pharmaceutical distributor, Amerisourcebergen will deliver the insomnia medication to a Defense Department facility located in Conshohocken, Pennsylvania by the scheduled completion date of June 27, 2023. No set aside provisions or subcontracting requirements were specified. The order was placed under an existing...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,122 to Amerisourcebergen Drug Corporation. The order is for 30 packages of 8mg Ramelteon tablets to be delivered from Amerisourcebergen's facility in Conshohocken, Pennsylvania by September 7, 2023. Amerisourcebergen, a subsidiary of Amerisourcebergen Corporation, will perform as the prime contractor under this order placed against an existing DLA contract vehicle. No set aside designation or...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,488.56 firm fixed-price delivery order covers the supply of Ramelteon 8 mg tablets for the DLA Troop Support Medical program. The contract has a period of performance through November 27, 2024 and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSELADelivery Order
This delivery order, valued at $2,751.58, was awarded on September 8, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp for the supply of Ramelteon 8 mg tablets (30-count packages). The contract represents a non-competitive, firm fixed-price delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, with performance occurring at its corporate office location in Conshohocken, PA. This award reflects AmerisourceBergen's established role as a primary vendor within the DLA's Medical Supply Chain, delivering a broad spectrum of pharmaceuticals and medical supplies to support Defense Health Agency operations and other federal healthcare customers worldwide. Ramelteon is a melatonin receptor agonist commonly used for sleep disorders, representing the type of specialized medication consistent with the company's portfolio of neurological and therapeutic treatments supplied to military healthcare programs. The delivery order is scheduled for completion by September 9, 2025, and operates under the existing IDC framework rather than as a separately competed procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/8/25 |